Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Metso Outotec’s Annual report for 2022 has been published

Metso Outotec Corporation’s stock exchange release on March 22, 2023, at 10:00 a.m. EETMetso Outotec has today, March 22, 2023, published its Annual report for 2022. The report consists of five sections that are Business overview, Financial review, Corporate governance statement, Remuneration report and GRI supplement.  Business overview comprises strategy, value creation and sustainability. Financial review consists of the Board of Directors' report, financial statements, Auditor’s report and investor information. Metso Outotec’s Board of directors’ report and financial statements is

BioStock: Xbrane's CEO on the launch of Ximluci in Europe

Together with its partner STADA, the biosimilar company Xbrane Biopharma is currently in the process of launching Ximluci, a biosimilar to the reference drug Lucentis for the treatment of a serious eye disease. In connection with the BioStock Investor Meeting, the company's CEO Martin Åmark talked about the product launch, the plans for the upcoming US launch and the licensing plans for the oncology portfolio.Watch the interview with Martin Åmark at biostock.se: https://www.biostock.se/en/2023/03/xbranes-ceo-on-the-launch-of-ximluci-in-europe/ This is a press release from BioStock -

Q4 Report - 31 December 2022

Flexion closes its strongest year to date with another record quarter. Total revenue grows by 108%, gross profit up 147% and adjusted EBITDA hits GBP 1.6mOctober-December 2022 performance · Total revenue increased by 108% to GBP 21.7m (10.5)* · Gross profit increased by 147% to GBP 3.7m (1.5) · Adjusted EBITDA[‡] increased to GBP 1.6m (0.4) · Adjusted profit before tax[#] increased to GBP 1.1m (0.6) · EPS amounted to GBP 2.78 pence (1.28 pence) · Adjusted EPS amounted to GBP 1.88 pence (1.32 pence) · Operating cash flow amounted to GBP 1.2m (0.5) · Cash and cash

Long-term incentive plan established for Raute's senior management and selected key persons

RAUTE CORPORATION STOCK EXCHANGE RELEASE MARCH 22, 2023 AT 9:45 A.M.   LONG-TERM INCENTIVE PLAN ESTABLISHED FOR RAUTE’S SENIOR MANAGEMENT AND SELECTED KEY PERSONS   Raute Corporation’s Board of Directors has decided on the commencement of a long-term incentive plan for the Group’s senior management and selected key persons. The decision includes a Performance Share Plan (“PSP”) as the main structure and a restricted Share Plan (“RSP”) as a complementary structure.   The purpose of the plan is to align the objectives of the owners and management in order to develop the

Annual Report 2022: Revenue growth of 45% and EBITDA growth of 20%

Company Announcement no. 02/202322 March 2023   The consolidated annual report for the period 1 January to 31 December 2022 was today approved by the Board of Directors. The full annual report is attached to this company announcement and can be found on our web site under www.wirtek.com/Investor-relations. CEO Michael Aaen comments: “We are pleased to report that despite a challenging macroeconomic environment during 2022, Wirtek still achieved great results with revenue growth of 45% and EBITDA growth of 20%. We expect double-digit organic revenue growth during 2023 in the

Swedish energy company selects Sectra’s service to protect critical systems against unauthorized access

Linköping – March 22, 2023 – International cybersecurity and medical imaging IT company Sectra  (STO: SECT B) has received an order for its Sectra Managed Detection and Response monitoring solution from Jönköping Energi. Proactive monitoring of critical systems will enable risks and vulnerabilities to be detected before they become a threat to day-to-day operations and thus to the region’s electricity supply.“We work every day to maintain a high level of delivery reliability in our electricity grid. We conduct maintenance and service on the grid to reduce the number of

Alfa Laval completes acquisition of innovative friction reduction technology

In 2021, Alfa Laval acquired a minority stake in the Netherland-based company Marine Performance Systems (MPS) with an option to acquire the remaining part later. Now Alfa Laval has executed that option and completed the acquisition to own 100 percent of MPS. The closing date for the acquisition was 21 March 2023. MPS’ innovative technology significantly reduces the friction from vessels when sailing, resulting in fuel savings.Friction between the hull and the water when sailing is the most significant driver of a vessel’s fuel consumption, and the cost of fuel represents up to 60 percent

Notice convening the Annual General Meeting of Nobia AB (publ)

The shareholders of Nobia AB (publ), reg. no. 556528-2752 (“Nobia” or the “Company”), are hereby given notice of the Annual General Meeting to be held on Thursday, April 27, 2023 at 13:00 CEST at S:ta Clara, Klarabergsviadukten 90, Stockholm.Right to participate in the Annual General Meeting: Shareholders who wish to participate in the Annual General Meeting must: firstly be included in the shareholders register maintained by Euroclear Sweden AB (“Euroclear”) as of Wednesday, 19 April, 2023; and,secondly notify Nobia of their participation at the Annual General Meeting

Publication of Biohit Oyj Renumeration Report 2022

Biohit Oyj Renumeration Report March 22, 2023 at 9:30 am local time (EET) Biohit Oyj’s Remuneration Report for the Governing Bodies is published today in PDF format. The Remuneration Report for the Governing Bodies is attached to this stock exchange release and also available at https://www.biohithealthcare.com/en/investors/. Additional information: CEO Jussi Hahtela, Biohit Oyjtel. +358 9 773 861investor.relations@biohit.fiwww.biohithealthcare.com  Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company.

Implantica to repurchase own shares

Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, announces that the Board of Directors has decided to utilize the authorization given by the Annual General Meeting (AGM) on May 10, 2022, to repurchase own Shares (Swedish Depository Receipts representing class A shares in the company).The repurchase will start at the earliest on March 22, 2023, and may be conducted on one or more occasions until the next Annual General Meeting on May 25, 2023. The number of Shares to be acquired shall not exceed 200,000. The repurchased Shares will

Atlas Copco publishes its Annual Report for 2022

Nacka, Sweden, March 22, 2023: Atlas Copco has today published its Annual Report for 2022. It was another year with record orders, revenues, and operating profit.“We continue to focus on delivering value to our customers and continuously investing in people and innovation,” said Mats Rahmström, President and CEO of Atlas Copco Group. “During 2022, we continued our investments in R&D and entered new growth platforms. The combination of organic growth and successful acquisitions has shaped us into the Group we are today, and we continue to look for new technologies and segments that

Svenska Aerogel’s sustainability work is ISO 26000 verified – becomes the first Swedish listed company to be verified

Svenska Aerogel continues to develop its sustainability work. Now the company has become the first Swedish listed company to be verified according to ISO 26000, an international standard focusing on corporate social responsibility (CSR). The verification has been carried out by an accredited third party, VERIFY Agency of Sweden, which has reviewed Svenska Aerogel’s sustainability work as well as the self-declaration of the work.Tor Einar Norbakk, CEO of Svenska Aerogel: “The work that led to the ISO verification of our sustainability processes complements our already certified and

Crunchfish AB appoint new CEO of Crunchfish Gesture Interaction AB

Crunchfish have appointed Fredrik Clementson as the CEO of Crunchfish Gesture Interaction AB. Fredrik will replace Joakim Nydemark as head of the subsidiary. Simultaneously Patrik Lindeberg will take over the role as Chief Operating Officer Crunchfish AB from Joakim Nydemark. As earlier communicated , Joakim Nydemark, Chief Operating Officer Crunchfish AB and CEO of Crunchfish Gesture Interaction AB leaves his operational roles at Crunchfish and is proposed to join its board of directors. A recruitment process was

Publication of Biohit Oyj Annual Report 2022

Biohit Oyj Annual Financial Report March 22, 2023 at 09:30 am local time (EET) Biohit Oyj’s Annual Report 2022 is published today in PDF and XHTML format. The annual report contains financial statements for 2022, the Report of the Board of Directors and Corporate Governance Statements. Information in ESEF format has not been audited. Annual report is published in Finnish and English, and it can be read and downloaded from Biohit company website: Annual Reports - Biohit Healthcare  CEO Jussi Hahtela, Biohit Oyj tel.

NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)

The shareholders in Prostatype Genomics AB (publ) reg. no. 556726-0285 (the “Company”) are hereby convened to the extraordinary general meeting on Friday 21 April 2023 at 10 AM at the Company´s office on Gustaf III:s Boulevard 34, 169 73 Solna.Right to participate in the general meeting Shareholders who wish to participate at the extraordinary general meeting shall: · on Thursday 13 April 2023 (the record date), be registered in the share register kept by Euroclear Sweden AB in their own names (not nominee-registered shares), and · notify the Company of his or her intention to

Dignitana enters Hong Kong market with leading distributor Science International Corporation

Scalp cooling innovator Dignitana AB  has signed Science International Corporation , a leading distributor for medical devices, to launch The DigniCap Scalp Cooling System in Hong Kong and Macao. Science International now becomes the exclusive provider of DigniCap in Hong Kong and Macau to minimize hair loss from chemotherapy. The company has already purchased two DigniCap Delta devices to introduce Dignitana’s clinically superior solution to the region.“Now is the time to bring this life-changing solution to our cancer patients,” said

BioStock: Patents and study in focus for Promore Pharma

When Promore Pharma looks back on 2022, it can look back on an eventful year with several important milestones achieved. 2023 does not promise to be any less hectic, in November the company announced that the results from the PHSU05 study with ensereptide for scarring on skin are expected to be available as early as April 2023. BioStock talked to CEO Jonas Ekblom about the past year and what awaits Promore Pharma.Read the full article about Promore Pharma at biostock.se: https://www.biostock.se/en/2023/03/patents-and-study-in-focus-for-promore-pharma/ This is a press release from

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release March 22, 2023 at 9:10 a.m. Nokian Tyres has received an announcement from Bank of America Corporation on March 21, 2023, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the total holding in Nokian Tyres shares and voting rights owned by Bank of America Corporation exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on March 20, 2023. The total shareholding of Bank of America Corporation in Nokian Tyres has increased to 7,378,228

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 78 - 22 MARCH 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 40/23 and 42/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

XNK presents at the 8[th] Innate Killer Summit in La Jolla, San Diego

XNK Therapeutics AB today announced its extensive participation at the 8[th] Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.The Annual Innate Killer Summit is the largest and leading technical, industry-focused, end-to-end innate immune cell therapy meeting to explore frontiers in immunobiology, genetic modification, clinical translation, scalable manufacturing, cryopreservation, and CMC. Over 200 experts from both pharmaceutical industry and academia participate to advance the clinical and phase development of NK, macrophage, γδT and NKT cell therapies for liquid and

Positive FDA Feedback to Progress Bexmarilimab

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Inside Information: Faron Announces Positive US Food and Drug Administration (FDA) Feedback to Progress Bexmarilimab as a Monotherapy in Solid Tumors       Green light for continued clinical development after data package review       Alignment with company’s selection of 1 mg/kg IV once-every-3-weeks (Q3W) as dose for further evaluation       Supportive of biomarker-driven approach with CLEVER-1 staining of tumor biopsy Company announcement, March 22, 2023 at 03:00 AM (EDT) / 07:00 AM (GMT) / 09:00 AM (EET) Inside

THE LAST DAY FOR TRADING IN THE WARRANTS TO 4 AND TO 5 IS TODAY, 22 MARCH 2023

PRESS RELEASE THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH ACTION IN WHOLE OR IN PART IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN CHROMOGENICS AB (PUBL). SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.Today, 22 March 2023, is the last day for trading in warrants of series TO 4 and TO 5 ("Warrants") issued in connection with

There are no items matching the current filter
There are no more items matching the current filter
Back to top